The Department for Health and Social Care has asked NICE to carry out an evaluation of tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113. We have recently invited stakeholders to respond to a written consultation on the draft scope.
The company that market tislelizumab have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience.
If you have any comments or concerns, please contact the project manager for this scoping exercise, Emily Richards via email on emily.richards@nice.org.uk).
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 5113 |
Project Team
| Project lead | Emily Richards |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 March 2025 - 16 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5113 |
| 16 April 2025 | Suspended. The Department for Health and Social Care has asked NICE to carry out an evaluation of tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that market tislelizumab have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience. If you have any comments or concerns, please contact the project manager for this scoping exercise, Emily Richards via email on emily.richards@nice.org.uk). |
| 19 March 2025 | In progress. Scoping commencing |
| 04 June 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-May 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 01 December 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 04 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 April 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 April 2022 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual